Építés alatt – nem éles oldal
Belépés
Visszavonva1. fázis

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

A legfontosabb adatok

Ki végzi
Medical University of South Carolina
Hol
Charleston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
1. fázis
Kezdés
2024. okt. 1.
Befejezés
2024. okt. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Allogeneic Mesenchymal Stromal Cells
A regiszteradat frissítve
2024. október 30.
Miért állt le
Funding

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing
  • Patient or their surrogate is willing and able to provide written informed consent and comply with all protocol requirements
  • Diagnosis with Mild or Moderate Pneumonia not requiring mechanical ventilation: Patient must have at least one of the following features:; Bilateral pneumonia present on chest radiograph or computed tomography ii. Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) on arterial blood gas showing: >100mmHg and ≤ 300mmHg regardless of oxygen dose at time of testing; Pulse oxygen saturation (SpO2) at rest ≤ 93% or any degree of hypoxia requiring supplemental oxygen
  • Patient agrees to storage of specimens for future testing
  • Willingness to undergo mechanical ventilation for worsening

Ki nem vehet részt

  • Intubation with mechanical ventilation prior to study enrolment. High flow nasal cannula and non-invasive mechanical ventilation is allowed
  • History of long-term use of immunosuppressive agents including prednisone dose >5mg daily over the 30 days prior to enrollment
  • Obstructive pneumonia induced by lung cancer or other known causes
  • Significant comorbid illness likely to impact the outcome of COVID-19 including but not limited to active malignancy other than skin cancer
  • History of severe chronic respiratory disease and requirement for long-term oxygen therapy
  • History of moderate and severe liver disease (Child-Pugh score >12)
  • History of deep venous thrombosis, pulmonary embolism, cerebral vascular disease within the last 3 years
  • Known HIV, hepatitis virus, or syphilis infection
  • Co-Infection of tuberculosis, influenza virus, adenovirus and other respiratory infection virus
  • Allergy to diphenhydramine, or hydrocortisone
  • Any condition unsuitable for the study as determined by the investigators
  • Receipt of experimental therapy for COVID-19 with the exception of convalescent plasma, dexamethasone or another corticosteroid, or remdesivir in an open label study
  • Estimated or actual rate of creatinine clearance < 15 ml/min
  • Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses
  • Patients who are participating in other therapeutic clinical trials within 30 days of consent
  • Undergoing hemodialysis or peritoneal dialysis
  • Substance abuse sufficient that the patient is unlikely to comply with testing requirements
  • Moribund patient not expected to survive > 24hours
  • Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period

Helyszínek itt: Egyesült Államok

  • Medical University of South CarolinaCharleston, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an open-label phase 1 clinical trial of allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia will be given 2 doses of MSCs at days 1 and 3 after consent. The safety of intravenous infusion will be tested and course of the oxygen response to treatment over 90 days will be evaluated.

A vizsgálat csoportja

  • Allogeneic Mesenchymal Stromal Cell infusionA vizsgált kezelés

    Intravenous infusion of 1.25-1.5 x 10\^6 cells/kg with a maximal dose of 100 x 10\^6 cells on days 1 and 3 after study enrollment.

    Kezelés: Allogeneic Mesenchymal Stromal Cells

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Safety and Tolerability of Allogeneic Umbilical Cord Derived Mesenchymal Stromal Cells (UC-MSCs) to Limit COVID Associated ComplicatioNs: an Open Label, Phase 1 Study in Hospitalized Patients (SAMPSON-1)
A regiszteradat frissítve
2024. október 30.